Closure Medical Corporation  
Closure Medical Corporation
News   Contact Us   Site Map   Home  
About UsHistoryMilestonesManagement Team
About Us
Our Products
Medical Professionals
Consumers
Prospective Employees
Client Login
 

About Us: History

Closure Medical Corporation was formed in 1997 but traces its roots back to 1971. The unifying thread of our early years to the present day is a singular commitment to revolutionize healing through medical innovation.

In 1971, Medtronic, Inc.formed a small company called Population Research, Inc. to develop a device for voluntary female sterilization (which was first legalized in the United States in 1967). The Femcept™ device was designed to deliver a small amount of a sclerotic agent (methyl cyanoacrylate) to occlude the fallopian tubes. This device never gained clearance from the U.S. Food and Drug Administration (FDA), and by 1982, Population Research, Inc. lost its financial backing.

That year, a spin-off was started and relocated to Raleigh, North Carolina. Bionexus, Inc. was a privately funded company which continued to work on the Femcept™ device and other applications for cyanoacrylate technology. Bionexus developed two n-butyl cyanoacrylate products (Avacryl® and Nexacryl™ adhesives) and one 2-octyl cyanoacrylate product for veterinary use (Nexaband® adhesive). The adhesives for human use were never commercialized, and in 1987, Bionexus, Inc. lost funding.

From Bionexus, Vector Medical, Inc. was formed in 1987 and then renamed CRX Medical, Inc. CRX Medical abandoned the Femcept™ device and worked diligently toward achieving commercial launch of Avacryl® and Nexacryl™ adhesives and expanding the 2-octyl cyanoacrylate franchise with Octyldent® adhesive for dental use. The company received market clearance from the FDA in May 1989 and signed a distribution agreement for Octyldent with the Alza Corporation.

In 1990, Sharpoint Development Corporation, owned by Bill and Rolf Schmidt, bought the assets of CRX Medical and formed a company called Tri-Point Medical, LLP. CRX sold all trademarks and intellectual property to Tri-Point, allowing it to focus on the development, manufacture and commercialization of tissue adhesive products for human use. In 1993, Tri-Point began the development of a product that would come to be known as DERMABOND Topical Skin Adhesive. Originally named Traumaseal™ adhesive, the product was first tested in a clinical study that commenced in 1996. By 1996, Tri-Point had signed a distribution agreement with Johnson & Johnson’s Ethicon Division to market and distribute the product. Tri-Point “went public” in 1996 with an initial public offering.

In 1997, Tri-Point Medical, LLP was renamed Closure Medical, Inc. The following year, DERMABOND adhesive was approved for commercial market release in the United States, making it the first (and still only) 2-octyl cyanoacrylate topical skin adhesive commercially available. Today we offer several adhesive devices based on the powerful DERMABOND platform.

In 1999, another milestone was reached when SOOTHE-N-SEAL® canker sore relief received approval from the FDA. A marketing and distribution agreement with Colgate the next year launched our first consumer product. This was followed by the 2002 launch of BAND-AID® Brand Liquid Adhesive Bandage, which is distributed by Johnson & Johnson Consumer Products Company. Other consumer products are under consideration at this time.

Closure Medical’s vision to revolutionize healing does not stop at the surface! For many years, Closure scientists have been pursuing the most formidable challenge yet: creating a strong, safe, easy to use tissue sealant and surgical adhesive that would be completely biocompatible and biodegradable within the human body. In the fourth quarter of 2003, Closure commenced human clinical trials in the United States for its new vascular sealant. The result of years of rigorous research, this product is just the beginning in our pursuits to solve many unmet surgical needs in side the human body.

While Closure Medical may have a complicated family tree, the men and women who develop and make our products are committed to our goal of creating medical devices to revolutionize healing. Today our products are in doctor’s offices, operating suites, emergency rooms, and medicine cabinets all over the world.

 

Real People. Real Healing.